Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.16 AUD
Change Today 0.00 / 0.00%
Volume 19.8K
As of 10:10 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

immuron ltd (IMC) Snapshot

Open
A$0.16
Previous Close
A$0.16
Day High
A$0.16
Day Low
A$0.16
52 Week High
03/28/14 - A$0.32
52 Week Low
03/25/15 - A$0.16
Market Cap
12.0M
Average Volume 10 Days
23.4K
EPS TTM
A$-0.05
Shares Outstanding
75.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMMURON LTD (IMC)

Related News

No related news articles were found.

immuron ltd (IMC) Related Businessweek News

No Related Businessweek News Found

immuron ltd (IMC) Details

Immuron Limited, a biopharmaceutical company, researches, develops, and sells polyclonal antibodies for the treatment and prevention of various diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. Its platform technology enables the development of medicines that target a range of medical needs, such as infectious diseases, immune mediated disorders, and cancers. The company commercializes its platform derived products through a range of regulatory pathways, including prescription, medical foods, over-the-counter medicines, and dietary supplements. It markets Travelan, a natural product to prevent infection by enterotoxigenic escherichia coli, which is the cause of travellers’ diarrhoea. The company is also developing IMM 124-E, a natural product for the treatment of fatty liver and non-alcoholic steatohepatitis/Type 2 diabetes, which is under Phase II clinical trial; IMM 529 for the treatment of clostridium difficile infection; IMM-363 to treat of side effects caused by chemotherapy or radiation; and IMM-160 to reduce tumour size and suppress liver cancer. Immuron Limited was founded in 1994 and is based in Southbank, Australia.

16 Employees
Last Reported Date: 08/29/14
Founded in 1994

immuron ltd (IMC) Top Compensated Officers

Interim Chief Executive Officer and Vice Pres...
Total Annual Compensation: A$220.0K
External Advisor
Total Annual Compensation: A$192.0K
Compensation as of Fiscal Year 2014.

immuron ltd (IMC) Key Developments

Immuron Ltd Enters Agreement with Linker Holdings Ltd for the Sale of Travelan in the People's Republic of China, Hong Kong and Macau

Immuron Ltd. has entered an agreement with Linker Holdings Ltd. for the sale of Travelan in the People's Republic of China, Hong Kong and Macau. Under the agreement, Linker has the exclusive rights to market, distribute and sell Travelan as a functional food and a dietary supplement in its licensed territory and has undertaken to contractually comply with specified annual minimum purchase obligations.

Immuron Ltd Enters an Agreement with Immune Biologies Pty Ltd for the Development and Commercialisation of IMM-124E for the Treatment of Short-Term Alcohol-Induced Liver Toxicity

Immuron Ltd. has entered an agreement with Immune Biologies Pty Ltd. for the development and commercialisation of IMM-124E for the treatment of short-term alcohol-induced liver toxicity. Under the agreement, Immune Biologies will carry out clinical trials designed to test the efficacy of IMM-124E for the prevention and/or treatment and/or amelioration of short-term alcohol-induced liver toxicity. The principle underlying these studies is that the anti-LPS activity of IMM-124E is the same underlying mechanism that governs the treatment of both non-alcoholic steatohepatitis (NASH) and alcoholic steatohepatitis (ASH), thus enabling the testing and use of IMM-124E in this third short-term clinical indication. Pending a successful outcome of the clinical trials to be undertaken by Immune Biologies, Immuron will sell the IMM-124E to Immune Biologies under a worldwide licence for the use of IMM-124E specifically for toxicity associated with short-term alcohol intake.

Immuron Limited Announces the Resignation of Amos Meltzer as Interim Chief Executive Officer

Immuron Limited announced that it has received a letter of resignation from its Interim Chief Executive Officer (CEO) Mr. Amos Meltzer. Mr. Meltzer has agreed to be available to assist beyond his 3-month notice period, if required, to facilitate a smooth transition to a new CEO.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMC:AU A$0.16 AUD 0.00

IMC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMC.
View Industry Companies
 

Industry Analysis

IMC

Industry Average

Valuation IMC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.5x
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMURON LTD, please visit www.immuron.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.